Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 3/20 | 0.37 |
| ▸ | WNT3 | P56703 | 1/20 | 0.36 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | YAP1 | P46937 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16714976 | 1.00 | KLK7 (0.37) | KLK7WNT3SFRP1STSGPR119 | |
| SCHEMBL16612125 | 0.88 | KCNA5 (0.35) | KCNA5 | |
| SCHEMBL16611362 | 0.88 | KCNA5 (0.35) | KCNA5 | |
| SCHEMBL15366663 | 0.86 | KMT2A (0.41) | STSAGTR2KMT2AL3MBTL1 | |
| SCHEMBL20402402 | 0.86 | STS (0.43) | STSGPR119JAK2JAK1YAP1 | |
| SCHEMBL15799761 | 0.86 | STS (0.43) | STSGPR119JAK2JAK1YAP1 | |
| SCHEMBL15799760 | 0.86 | STS (0.43) | STSGPR119JAK2JAK1YAP1 | |
| SCHEMBL15208521 | 0.86 | STS (0.43) | STSGPR119JAK2JAK1YAP1 | |
| SCHEMBL15364635 | 0.85 | STS (0.51) | STSGPR119JAK2JAK1YAP1 | |
| SCHEMBL15364851 | 0.85 | YAP1 (0.41) | STSGPR119JAK2JAK1YAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | KLK7 4463/4885WNT3 3359/4885SFRP1 585/4885 |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | ME1, FN1, FNTB | KLK7 4730/4885WNT3 1023/4885SFRP1 2309/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | KLK7 4463/4885WNT3 3359/4885SFRP1 585/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | KLK7 4463/4885WNT3 3359/4885SFRP1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.